Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine

Inclusion Criteria:

Availability of signed and dated informed consent of the volunteer to participate in the
study.

Healthy male and female volunteers aged 18 and above. Ability and voluntary desire to
independently keep records in the Self-Observation Diary, as well as to carry out all the
repeated visits provided for in the study for control medical observation.

The voluntary desire of females to use methods of reliable contraception throughout the
entire period of their participation in the study.

Negative results for IgM and IgG antibodies to SARS-CoV-2. Absence of COVID-19 diagnosis in
history. Absence in the last 14 days of close contact with persons suspected of being
infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with
laboratory.

Exclusion Criteria:

Aggravated allergic history, drug intolerance, including hypersensitivity to any of the
components of the study drug, as well as a history of serious adverse events during vaccine
administration (such as allergic reactions, respiratory failure, angioedema, abdominal
pain).

Acute illness with a fever (body temperature ≥37.1 ° C) at the time of screening.

History of chronic alcohol abuse and/or drug use. Positive results for antibodies IgM, IgG
to SARS-CoV-2 Women with a positive urine pregnancy test. Simultaneous treatment with
immunosuppressive drugs, incl. corticosteroids (2 weeks) 4 weeks prior to study drug
administration.

Acute or chronic clinically significant lesions of the lungs, cardiovascular system,
gastrointestinal tract, liver, blood system, skin, endocrine, neurological and psychiatric
diseases or impaired renal function (asthma, diabetes, thyroid disease, arrhythmia, heart
attack myocardium, severe hypertension not controlled by drugs, etc.), identified based on
the data of the medical history, physical examination, which, according to the researcher,
may affect the study result.

History of platelet disorder or other blood clotting disorders that may cause
contraindications to intramuscular administration.

History of leukemia or neoplasm. Persons with autoimmune diseases. A history of
Guillain-Barré syndrome or other neuroimmunological diseases. Subjects who received
antiviral drugs, immunoglobulins or blood transfusions or any other investigational drug
within 4 weeks prior to study drug administration; Subjects who received anti-inflammatory
drugs 2 days prior to study drug administration; Participation in any other clinical
research within the last 6 months. Subjects with regard to whom there is a concern that
they will not comply with the requirements of the study, or persons with severe physical or
mental disabilities that may affect the completion of the study.

Voluntary refusal to study. Vulnerable research subjects.